Increasing use of tobacco-based smoking products coupled with rising cases of respiratory diseases worldwide will drive erdosteine market size in the coming years. Erdosteine is basically a mucolytic medicine that helps in treating symptoms associated with diseases like chronic bronchitis. Indeed, smoking is said to be the key reason for a significant rise in such conditions while other causes including long-term exposure to air pollution, fumes and dust from the environment and repeated cases of acute bronchitis.
U.S. Erdosteine Market Size, By Application, 2018 & 2025, (Tons)
Environmental issues and other factors also result in both increased mucus production and decreased ability to clear phlegm out. Nevertheless, with erdosteine, patients can easily cough up excess developed mucus owing to the drug’s ability to make congestion less thick and sticky. Rising number of chronic bronchitis cases, primarily due to growing use of tobacco-based smoking products, is anticipated to expand erdosteine market size significantly over the coming years.
For instance, as per the World Health Organization (WHO), tobacco-based products kill at least 8 million people each year. Moreover, the product is also identified as the key contributor to chronic obstructive pulmonary disease (COPD), a condition wherein a patient suffers from painful cough and agonizing breathing difficulty due to build-up of pus-filled mucus in lungs.
Reportedly, the risk of suffering from COPD is high among individuals who start smoking at a very young age, or even to those who are exposed to second-hand smoking. In fact, reports from the U.S. Department of Health & Human Services (HHS) claim that, in 2018, around 4.9 million middle and high school students were using tobacco.
Meanwhile, the Center for Disease Control (CDC) states that in the U.S., each day, about 2,000 youngsters, under the age of 18 years, have their first cigarette, while over 300 under 18 years develop a habit of smoking daily.
With growing illegal use of tobacco, cases of respiratory illness will rise significantly over the coming years, supplementing the need for essential therapies like erdosteine. Moreover, expanding geriatric population being more prone to respiratory diseases is also expected to add impetus to erdosteine market size.
Some of the key factors that are anticipated to stimulate global erdosteine market outlook:
Increased cases of COPD worldwide – specifically in the U.S.
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide and has imposed a considerable burden on U.S. healthcare sector. As mentioned earlier, smoking is the leading cause of COPD and is remarkably common among Americans. For instance, according to CDC, the country had nearly 38 million cigarettes smokers in the year 2016. Smoking kills more than 480,000 Americans each year and for every person who dies due to smoking related diseases, there are 30 Americans who continue to live with such diseases and be a burden on the country’s healthcare system.
In addition to smoking, oxidative stress, inflammation and mucus hypersecretion are also some factors that drive the pathophysiology of COPD. However, with novel mucoactive drugs like erdosteine, doctors are able to effectively address problems associated with COPD. Reportedly, the drug exhibits anti-inflammatory and antioxidant properties, and also regulates bacterial adhesiveness or prevention of exacerbations.
Clinical data also suggested that erdosteine, as an add-on therapy, could reduce the exacerbation rate and time spent in hospital, and improve health-related QoL in COPD patients. Thus, with growing prevalence of COPD, the erdosteine market will register growth in the U.S. Moreover, rising consumer awareness regarding erdosteine will also foster business expansion.
Growing demand of erdosteine across global pharmaceutical sector
Respiratory diseases have become one of the most significant healthcare and economic burdens across the globe. In the U.S., tobacco smoke is a key contributor to chronic respiratory illnesses, while exposure to air pollutants at workplace and home, viral infections and genetic factors have further contributed as some key factors. Reportedly, with over 600,000 deaths and around six million admissions in hospitals costing over €380 billion each year, respiratory illness is also a significant factor in the European healthcare and pharmaceutical sectors.
While on a global scale, respiratory diseases are amongst the leading causes of death, with chronic obstructive pulmonary disease (COPD) ranking third and fourth in Western Europe and worldwide. Nevertheless, stringent government regulations to counter smoking habits along with rising consumer consciousness toward customized medicines and pharmaceutical products will stimulate erdosteine market size. Moreover, collaborations and federal support to initiate erdosteine-ralted research and development (R&D) is anticipated to boost erdosteine industry outlook.
For instance, in 2015, Recipharm AB announced an extension of its existing contract with Daewoong for manufacturing and supply of erdosteine API until 2025. Meanwhile, in 2019, the U.S. Food and Drug Administration (FDA) offered erdosteine the Orphan Drug Status?, a new indication for the treatment of bronchiectasis.
In essence, erdosteine, a mucolytic drug which helps in clearing mucus (phlegm) from lungs, is used to treat symptoms pertaining to excessive mucus production triggered by excessive smoking and environment contaminates. With rapid growth in global pharmaceutical and healthcare sectors coupled with rising usage of tobacco-based smoking products, erdosteine market size will exceed USD 150 million by 2025.